Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

6.41
+0.08001.26%
Pre-market: 6.450.0400+0.62%06:00 EDT
Volume:2.21M
Turnover:14.18M
Market Cap:943.54M
PE:-10.94
High:6.50
Open:6.36
Low:6.29
Close:6.33
52wk High:6.52
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:1.50
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.57
PE(LYR):-12.09

Loading ...

Aclaris Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
Jun 03

Aclaris Therapeutics initiated with an Outperform at LifeSci Capital

TIPRANKS
·
Jun 02

Aclaris Therapeutics Initiated at Buy by Dellorusso on Diversified Immunology Pipeline and Multi-Year Catalyst Potential

TIPRANKS
·
Jun 02

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler

TIPRANKS
·
May 11

Guggenheim Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)

TIPRANKS
·
May 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

Analysts Offer Insights on Healthcare Companies: Medline (MDLN), Aclaris Therapeutics (ACRS) and Alkermes (ALKS)

TIPRANKS
·
May 11

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

GlobeNewswire
·
May 08

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

TIPRANKS
·
May 07

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

TIPRANKS
·
May 07

Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate

Benzinga Earnings
·
May 07

Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Aclaris Therapeutics Q1 net loss widens on higher R&D spending

Reuters
·
May 07

BRIEF-Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16

Reuters
·
May 07

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewswire
·
May 07

Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 06

Aclaris Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
May 05

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

TIPRANKS
·
May 05

Aclaris Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
May 05